Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$2.34
+0.21%
Mkt Cap $307.64M
Analyst Ratings
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
Implied Upside
+178.4%
Consensus $6.50 vs current $2.34
NASDAQ·Healthcare·Biotechnology
$2.34
+0.21%
Mkt Cap $307.64M
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
+178.4%
Consensus $6.50 vs current $2.34